



June 25, 2018

For Immediate Release

Reborna Biosciences, Inc.
Mitsubishi UFJ Capital Co., Ltd.

Reborna Biosciences Completes Seed-Round Private Placement of New Shares

Reborna Biosciences, Inc. (representative director: Koji Fuji; address: Fujisawa, Kanagawa Prefecture; “Company”), a research and development start-up focusing on the field of rare genetic diseases, is pleased to announce that it has raised a total of 256 million yen through a private placement of new shares to Takeda Pharmaceutical Company Limited (“Takeda”) and to a fund*¹ managed by Mitsubishi UFJ Capital Co., Ltd. The capital raised will be used primarily to finance the research and development of TEC-1, a potential therapeutic drug for spinal muscular atrophy (“SMA”) licensed by Takeda, and of other preclinical assets.

Receiving other support for its research and development activities from Takeda, the Company has already started operations at its office in Takeda’s Shonan Health Innovation Park (“Shonan iPark”).

“We are grateful for this support, which will allow us to swiftly move forward with our research and development programs that explore therapeutic drugs for SMA and other rare genetic diseases,” said Koji Fuji, the Company’s founder and representative director. “We believe that our drug discovery technology will enable low-molecular compounds to target ribonucleic acid, a method deemed impossible to achieve with existing techniques. Harnessing this technology, we aim to provide new disease-modifying drugs for patients suffering from rare genetic diseases and their families in the future. We consider ourselves very fortunate to be able to bring our cutting-edge drug discovery technology to fruition at Shonan iPark.”

“Reborna Biosciences’ philosophy agrees with that of Shonan iPark, which dictates that we translate revolutionary partnerships and technologies into health innovations meaningful to patients,” said Shonan iPark General Manager Toshio Fujimoto. “We will continue to support Reborna Biosciences in hopes that a product made possible by its transformative technology will be delivered to patients as early as possible.”

*1. Mitsubishi UFJ Life Science No.1 Investment Limited Partnership, which was established jointly by MUFG Bank and Mitsubishi UFJ Capital in February 2017 with the aim of

contributing to stimulating drug discovery and other efforts in the life sciences. This 10 billion yen fund with a maturity of 12 years goes beyond simply investing in biotechnology start-ups; it also focuses on investing in drug discovery efforts in academia as well as in-house development projects of and carve-outs from pharmaceutical companies.

For further information, please contact:

Corporate Planning Office
Reborna Biosciences, Inc.
Tel: +81-466-32-1124
Email: info@rebornabiosciences.com
Website: <http://rebornabiosciences.com>

Corporate Planning Department
Mitsubishi UFJ Capital Co., Ltd.
Tel: +81-3-5205-8581